In a report published Wednesday, Credit Suisse analyst Ravi Mehrotra reiterated an Outperform rating on Biogen Idec BIIB, and raised the price target from $255.00 to $290.00.
In the report, Credit Suisse noted, “We are raising EPS forecasts primarily based on higher Tecfidera and Hemophilia franchise peak sales estimates. We are taking our Tecfidera peak sales from $4.2B to $5.2B in 2018 and the Hemophilia franchise from $1.0B to $1.5B in 2020. We also have made other house-keeping changes to the model results in 7-17% and 10-19% top- and bottom-line increase respectively from 2014 to 2018. Our 2013, 2014, and 2015 EPS are $8.45, $11.54, and $14.02 respectively.”
Biogen Idec closed on Tuesday at $244.92.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in